Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medical Device Deals Update, April 2015

Executive Summary

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced March–April 2015.

You may also be interested in...



Over The Counter 22 Apr 2024: Helping Consumers ‘Tune In’ To Reliable Health Information, With Kaizo PR's Anita Nahal

“Consumers are rewriting the rules when it comes to where they are going for information and the type of information they are looking for,” reports Kaizo’s Anita Nahal, speaking to HBW Insight’s Over the Counter podcast about the agency’s latest Communicating Health Messages report. Trust in social media has increased, and personal beliefs and lived experiences are playing a larger role in shaping attitudes to health information, explains Nahal, who is director at the London-based PR agency. However, consumers are also continuing to “tune-out” from health messages and be less critical of sources. To help consumers navigate this new reality, consumer health companies need to adapt, rethink and reset their communication strategies, Nahal advises.

First Of Its Kind: UK Hospital To Apply For ADA-SCID Gene Therapy Approval

Great Ormond Street Hospital is piloting a new approach to gene therapy delivery in which it will submit a marketing authorization application to the UK regulator for a lentiviral gene therapy used to treat ADA-SCID, a rare disease.

China VBP, Localization And Other Strategies - How Far And Which Way?

Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues. 

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT035895

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel